Registrational Phase 3 study for advanced melanoma immunotherapy delivered with PharmaJet's IM Needle-free System planned for ...
TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...
Ever-smokers receiving immunotherapy for gastric and esophageal cancers showed better survival outcomes but higher relapse ...
Cleveland Clinic researchers have discovered that bacteria inside cancerous tumors may be key to understanding why ...
Studies published in Nature Cancer reveal how bacterial presence in head and neck cancers affects treatment response, ...
Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent ...
The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).
A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to ...
The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% ...
The gut microbiome has been shown to influence tumor growth and contribute to therapeutic resistance. Scientists have ...
If you smoke and want to quit, call the national quit line at 1-800-784-8669 to speak with a confidential coach. In what ...
More peanut-allergic children receiving a 30 mg maintenance dose for peanut oral immunotherapy vs. avoiding peanut tolerated at least 443 mg and 1,043 mg of peanut protein at 1 year, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback